Continuing the effort to reduce the opioid epidemic’s impact on Ohio’s injured workers, BWC’s Board of Directors voted late last month to drop oxycodone from BWC’s formulary effective 6/1/19, replacing it with Xtampza ER. This followed a recommendation from BWC’s Chief Medical Officer Terry Welsh, who called Xtampza ER “an equally effective but harder-to-abuse drug.”
“Xtampza is sustained-release from oxycodone, like OxyContin, but it utilizes a unique abuse-deterrent technology that makes it difficult to manipulate – crush, snort or inject – for aberrant use,” said Welsh. “Thanks to technology, this just seems like the next responsible step to protect our injured workers from potential addiction and overdose death to dangerous drugs.”
BWC will phase out the use of oxycodone drugs over time allowing for weaning and/or switching to a different medication by 12/31/19. This follows best clinical practices and provides time for consultation with prescribing physicians, injured workers and injured worker representatives regarding the changes.This change is just another step in the multiple efforts BWC has made to help curb injured worker opioid addiction. Past changes have included the creation of a pharmacy and therapeutics committee, changes to the formulary and opioid prescribing guidelines that include a rule to hold prescribers accountable.
As your MCO
CareWorks of Ohio does not directly manage medications for injured workers. However, we are continually reviewing claims for medication relatedness and performing drug utilization reviews.
If you have questions regarding any prescription prescribed for your injured workers, please reach out to your assigned CareWorks of Ohio Case Manager at: 888.627.7586.
*Information from this article was provided by a publication from the Ohio Bureau of Workers’ Compensation.← Back